HC Wainwright Issues Negative Estimate for Rezolute Earnings

Posted by on Oct 1st, 2026

Rezolute, Inc. (NASDAQ:RZLT – Free Report) – Equities researchers at HC Wainwright cut their Q1 2027 EPS estimates for shares of Rezolute in a report released on Friday, September 25th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.57) EPS, Q1 2028 earnings at ($0.13) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.10) EPS, Q4 2028 earnings at $0.01 EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at ($0.14) EPS, FY2030 earnings at $1.42 EPS and FY2031 earnings at $2.94 EPS.

Other equities research analysts also recently issued reports about the stock. Guggenheim upped their target price on shares of Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, June 15th. Cantor Fitzgerald restated a “neutral” rating on shares of Rezolute in a report on Wednesday, June 3rd. HSBC upgraded shares of Rezolute to a “buy” rating in a research note on Friday, September 25th. Lake Street Capital initiated coverage on shares of Rezolute in a research report on Wednesday. They set a “buy” rating and a $9.00 price objective for the company. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Rezolute in a report on Friday, September 25th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Rezolute presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.44.

View Our Latest Stock Report on RZLT

Rezolute Stock Performance

Shares of RZLT opened at $4.14 on Tuesday. The stock has a market capitalization of $400.42 million, a PE ratio of -5.45 and a beta of 0.60. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.46. The company’s 50-day simple moving average is $4.54 and its 200-day simple moving average is $4.05.

Rezolute (NASDAQ:RZLT – Get Free Report) last released its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05).

Institutional Trading of Rezolute

Institutional investors have recently added to or reduced their stakes in the stock. AlphaCentric Advisors LLC raised its holdings in Rezolute by 6.2% during the first quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock worth $217,000 after purchasing an additional 4,171 shares in the last quarter. Auxano Advisors LLC bought a new position in Rezolute during the 2nd quarter valued at $52,000. Sequoia Financial Advisors LLC bought a new position in Rezolute during the 2nd quarter valued at $75,000. Jefferies Financial Group Inc. acquired a new position in shares of Rezolute during the 4th quarter valued at $35,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Rezolute during the 2nd quarter valued at $88,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Key Stories Impacting Rezolute

Here are the key news stories impacting Rezolute this week:

  • Positive Sentiment: Lake Street Capital initiated coverage with a Buy rating and a $9.00 price target. The target implies substantial upside from recent trading levels and adds a new bullish voice to Rezolute’s analyst coverage.
  • Positive Sentiment: Craig-Hallum upgraded Rezolute from Hold to Buy and raised its price target from $4.00 to $7.00. The upgrade signals improved confidence in the company’s outlook and was accompanied by a significantly higher valuation target. Craig-Hallum upgrades Rezolute to buy from hold
  • Positive Sentiment: HC Wainwright reiterated its Buy rating and $10.00 price target. Its long-range model projects Rezolute could become profitable, with estimated EPS of $1.42 in fiscal 2030 and $2.94 in fiscal 2031. HC Wainwright also raised its fiscal 2029 EPS forecast to a loss of $0.14 from a loss of $0.17 and increased its fiscal 2030 estimate sharply from $0.27 to $1.42.
  • Neutral Sentiment: Rezolute remains a development-stage company with expected losses in the nearer term. HC Wainwright forecasts fiscal 2027 EPS of negative $0.57 and fiscal 2028 EPS of negative $0.34, highlighting that the investment case depends heavily on future execution and potential commercialization.
  • Negative Sentiment: HC Wainwright reduced several near-term earnings forecasts. Estimates were lowered for fiscal 2027, fiscal 2028, second-quarter 2027 and fourth-quarter 2027, reflecting expectations for larger losses than previously projected. The firm nevertheless maintained its Buy rating and $10.00 target. Rezolute Stock Earnings Estimates Decreased by HC Wainwright

About Rezolute

(Get Free Report)

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.

Read More

Earnings History and Estimates for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.